CHLOROMYCETIN (chloramphenicol) by Pfizer is clinical pharmacology chloramphenicol is a broad-spectrum antibiotic originally isolated from streptomyces venezuelae . Approved for surface ocular infections involving the conjunctiva and/or cornea caused by chloramphenicol-susceptible organisms. First approved in 1953.
Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
CHLOROMYCETIN (chloramphenicol) is a broad-spectrum bacteriostatic antibiotic that inhibits bacterial protein synthesis by interfering with amino acid transfer to ribosomes. It is indicated for surface ocular infections of the conjunctiva and/or cornea caused by susceptible organisms and is administered topically as an ophthalmic solution. The drug was originally isolated from Streptomyces venezuelae and demonstrates minimal resistance development in staphylococci and many other bacterial species.
With LOE approaching and no Part D spending data available, this product faces declining commercial investment; expect team rationalization and shift toward cost management and generic transition support.
Clinical Pharmacology Chloramphenicol is a broad-spectrum antibiotic originally isolated from Streptomyces venezuelae . It is primarily bacteriostatic and acts by inhibition of protein synthesis by interfering with the transfer of activated amino acids from soluble RNA to ribosomes. It has been…
Worked on CHLOROMYCETIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
This product offers limited career growth potential; linked job count is zero, reflecting its legacy status and minimal commercial investment. Roles available are primarily defensive (regulatory maintenance, supply chain, legacy brand management) rather than strategic or growth-oriented.